Terence Flynn
Stock Analyst at Morgan Stanley
(1.67)
# 1409
Out of 5,347 analysts
208
Total ratings
60.20%
Success rate
6.52%
Average return
Main Sectors:
Top Industries:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
ARVN Arvinas | Maintains: Equal-Weight | 12 11 | 7.18 | 53.2% | 9 | May 9, 2025 | |
RCUS Arcus Biosciences | Maintains: Overweight | 24 22 | 8.91 | 146.91% | 6 | May 9, 2025 | |
BNTX BioNTech | Maintains: Overweight | 140 132 | 95.8 | 37.79% | 3 | May 6, 2025 | |
OGN Organon | Maintains: Equal-Weight | 15 10 | 9.22 | 8.46% | 10 | May 5, 2025 | |
UTHR United Therapeutics | Maintains: Equal-Weight | 346 348 | 318.42 | 9.29% | 9 | May 1, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 241 250 | 186.03 | 34.39% | 16 | Apr 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 164 169 | 155.02 | 9.02% | 21 | Apr 16, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1146 1124 | 737.72 | 52.36% | 19 | Apr 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 328 330 | 288.09 | 14.55% | 8 | Apr 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 69 63 | 14.81 | 325.39% | 2 | Mar 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 30 32 | 36.24 | -11.7% | 7 | Feb 14, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 113 106 | 76.83 | 37.97% | 16 | Feb 5, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 16 17 | 10.6 | 60.38% | 4 | Feb 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 56 11 | 6.86 | 60.35% | 5 | Jan 27, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 36 39 | 48.3 | -19.25% | 10 | Nov 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 31 | 23.46 | 32.14% | 17 | Oct 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 118 | 21.75 | 442.53% | 1 | Sep 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 36 | 3.5 | 928.57% | 1 | Jul 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 51 | 32.87 | 55.16% | 11 | Jul 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 121 168 | 101.26 | 65.91% | 6 | May 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 1 8 | 1.25 | 540% | 5 | Feb 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 25 12 | n/a | n/a | 9 | Oct 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 2880 | n/a | n/a | 1 | Jul 19, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 246 436 | 129.73 | 236.08% | 3 | Jun 14, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 35 | n/a | n/a | 1 | Jun 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 342 | n/a | n/a | 1 | Oct 5, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 54 | n/a | n/a | 3 | May 29, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | n/a | n/a | n/a | 2 | Oct 2, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 21, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Mar 13, 2017 |